STOCK TITAN

Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Fusion Pharmaceuticals (Nasdaq: FUSN), a clinical-stage oncology company, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 10:30 AM EDT. The presentation will be led by CEO John Valliant, Ph.D. A live webcast will be available on the company’s website, with a replay to be archived for 90 days. Fusion specializes in developing next-generation radiopharmaceuticals for cancer treatment, focusing on its lead program, FPI-1434, currently in Phase 1 trials.

Positive
  • None.
Negative
  • None.

HAMILTON, ON and BOSTON, April 14, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 10:30am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-bloom-burton--co-healthcare-investor-conference-301268680.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When will Fusion Pharmaceuticals present at the Bloom Burton & Co. Healthcare Investor Conference?

Fusion Pharmaceuticals will present on April 20, 2021, at 10:30 AM EDT.

Who is presenting on behalf of Fusion Pharmaceuticals at the conference?

CEO John Valliant, Ph.D. will present on behalf of Fusion Pharmaceuticals.

Where can I watch the Fusion Pharmaceuticals conference presentation?

The presentation will be available via live webcast on the company's website.

What is the focus of Fusion Pharmaceuticals' research?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines for oncology.

What is the status of Fusion Pharmaceuticals' lead program, FPI-1434?

FPI-1434 is currently in a Phase 1 clinical trial.

Fusion Pharmaceuticals Inc. Common Shares

NASDAQ:FUSN

FUSN Rankings

FUSN Latest News

FUSN Stock Data

1.83B
75.27M
0.47%
86.8%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
HAMILTON